Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

An Israeli study found patients taking Ozempic or similar weight-loss shots were twice as likely to suffer from a serious degenerative eye disease compared to those not on the medication.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision ...

Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency’s (EMA ...